May 24, 2026 a 05:00 pm

IDXX: Analysts Ratings - IDEXX Laboratories, Inc.

Historical Stock Grades

The latest data for IDEXX as of May 2026 shows a varied distribution of analyst ratings. The majority lean towards "Buy" or "Strong Buy," indicating optimism about the stock's potential performance. Notably, there is a single "Strong Sell" suggestion, reflecting some concerns among analysts.

Rating	Count	Score
Strong Buy	4
Buy	5
Hold	5
Sell	0
Strong Sell	1

Sentiment development

Over the past months, IDEXX has experienced fluctuations in analyst sentiment. Despite sustained ratings in "Strong Buy" and "Buy," an observable trend shows a slight increase in "Hold" recommendations, hinting at increasing caution. This shift could indicate a perceived plateau in the company's performance or market uncertainties.

• The overall number of analyst ratings has shown a slow but steady growth over the months.
• A consistent pattern of "Strong Buy" and "Buy" ratings suggests continued confidence.
• Recent increases in "Hold" ratings suggest analysts are hedging their expectations amid market conditions.

Percentage trends

The rating category distribution has seen subtle shifts recently. Though "Buy" and "Strong Buy" still constitute a significant portion of recommendations, the proportion of "Hold" ratings has been on the rise. This change reflects a more cautious outlook as some analysts assess wider market risks or company-specific factors.

• In recent months, there's been a slight reduction in "Strong Buy" percentage, with "Hold" ratings growing.
• Overall trends indicate increasing restraint, with fewer outright buy recommendations compared to a year ago.
• The last 6–12 months have shown a stable yet slightly more conservative approach among analysts.

Latest Analyst Recommendations

The latest analyst actions display a consistency in ratings, with a general bias towards maintaining existing recommendations. Notably, no changes in sentiment were observed in the most recent assessments.

Date	New Recommendation	Last Recommendation	Publisher
2026-04-28	Neutral	Neutral	UBS
2026-03-31	Buy	Buy	Stifel
2026-02-09	Neutral	Neutral	Piper Sandler
2026-02-05	Overweight	Overweight	Barclays
2026-02-03	Neutral	Neutral	UBS

Analyst Recommendations with Change of Opinion

Changes in analysts' opinions have been rather sporadic. The most notable shifts suggest some re-evaluation of IDEXX’s market position, mainly moving towards more cautious stances.

Date	New Recommendation	Last Recommendation	Publisher
2025-10-31	Buy	Hold	Stifel
2024-01-30	Neutral	Overweight	Piper Sandler
2023-08-02	Neutral	Overweight	Atlantic Equities
2022-07-25	Hold	Buy	Stifel
2022-07-21	Buy	Neutral	Goldman Sachs

Interpretation

The aggregate analyst sentiment reflects cautious optimism for IDEXX Laboratories, with slightly growing conservatism in recent months. While confidence remains largely intact, the increase in "Hold" recommendations could indicate a reassessment of industry dynamics or comparable company benchmarks. The stability in recommendations suggests underlying market factors are well understood, although perceived risks and rewards might be balancing on a finer line.

Conclusion

IDEXX Laboratories, Inc. presents a mixed yet promising investment scenario. The consistently strong "Buy" ratings underscore its robust market position, especially within the veterinary diagnostics sector. However, the modest creep of "Hold" opinions signals a watchful market stance, reflecting potential volatility or sectoral shifts. Investors might consider this balanced outlook in weighing the risks against anticipated returns. Ultimately, IDEXX remains a potentially rewarding holding, with the cautious advisory trend reflecting strategic prudence amidst broader market uncertainties.